Human Genome Sciences, GSK submit approval application for lupus drug

LONDON Human Genome Sciences has submitted an approval application for a treatment for lupus, development partner GlaxoSmithKline said Thursday.

The two companies are hoping to win approval for Benlysta (belimumab) as a treatment for systemic lupus erythematosus in patients who are receiving standard treatments.

The two companies are developing Benlysta under a codevelopment and commercialization agreement they entered in 2006.

Login or Register to post a comment.